Answers are grounded in this paper and cite their sources.
Cancer stem cells (CSC) are a small group of tumor cells capable of self-renewing, giving rise to new tumors, and resisting treatment, thereby causing recurrence and metastasis and representing a serious clinical problem. However, there are no approved therapies for their elimination, and limited information is available on the effects of current therapies on tumor stemness. A general consensus suggests that the anti-inflammatory and immunosuppressive tumor microenvironment promotes tumor stemness. Since we previously reported that ablation of the p50 NF-κB gene in the hematopoietic compartment (p50fl/flTie2-Cre mice) restores M1/Th1 antitumor immunity, we studied its effects on CSC and therapy resistance in models of fibrosarcoma and melanoma. Using p50fl/flTie2-Cre mice, we demonstrate that p50 NF-κB silencing impairs CSC development, their migratory capacity, and epithelial-mesenchymal transition (EMT), events known to correlate with tumor aggressiveness. Furthermore, we identify a clear antagonistic effect between Th1 and Th2 T cell polarization, with the former acting as inhibitors and the latter promoting the stemness phenotype. Consistently, while immunotherapy with anti-PD-1 promoted a marked reduction in CSC and tumor development, associated with increased levels of IFNγ, whereas concomitant administration of anti-IFNγ antibodies restored tumor growth and dissemination. Moreover, treatment with anti-IL-4 enhanced the antitumor effects of immunotherapy, reducing tumor cell stemness. Importantly, the antitumor effects of high-dose IFNγ and anti-IL-4 were confirmed in combination with doxorubicin chemotherapy. Overall, our data indicate that shifting the immune response toward a robust M1/Th1 state can significantly improve current immunotherapies and chemotherapies, by limiting CSC properties.
No takes yet. Share an insight, caveat, or question.
Consonni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: